• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Tenofovir prophylaxis linked with reduced risk of herpes simplex 2

byAimme Li, MDandKenan Celtik, MS
July 2, 2014
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Daily oral pre-exposure prophylaxis (PrEP) with tenofovir alone or in combination with emtricitabine in heterosexual individuals in high-risk populations was associated with a reduced risk of acquiring herpes simplex 2 (HSV-2). 

Evidence Rating Level: 1 (Excellent)

Study Rundown: PrEP with tenofovir with or without emtricitabine has been associated with protection against new HIV-1 infection in high-risk populations.  In vitro studies have also shown that intravaginal tenofovir gel is associated with reduced transmission of HSV-2.  Thus, this secondary analysis of randomized trials of tenofovir PrEP with or without emtricitabine for prevention of HIV sought to determine if this drug could also protect against HSV-2 infection in high risk populations.  The study found that daily oral dosing of tenofovir in high-risk populations was associated with a reduction in the rate of HSV-2 acquisition compared to placebo (hazard ratio 0.70, p0.047).  Interestingly, they found that PrEP was more protective against HSV-2 seroconversion in people whose HIV-1 positive partners were less immune-compromised with CD4 counts ≥0.350 x 109 cells/L.  A major strength of the analysis was the high degree of adherence to the treatment, which was unique compared to other trials of daily oral tenofovir.  However, the study is limited by its design as a secondary analysis of data from prior studies that were not devised to study HSV-2 infection.

Click to read the study, published today in the Annals of Internal Medicine

Relevant Reading: Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

In-Depth [secondary analysis]: This study was a secondary analysis within the larger (Partners PrEP) study of 4747 HIV-1 serodiscordant couples in Kenya and Uganda that were randomized to receive tenofovir (TDF), emtricitabine-tenofovir (FTC-TDF) or placebo. Within each of the three cohorts, individuals who did not have HIV-1 or HSV-2 at baseline were tested for their HIV-1 and HSV-2 status at 1, 3, 6, 12, 18, 24, 30, 36 months afterward. Of the 1498 people that were followed, 131 people developed HSV-2 positive status over 36 months of follow up. There was a statistically significant 30% reduction in incidence rate between those who received PrEP and those receiving placebo.  The incidence rates were 5.6 and 7.7 per 100 person-years respectively (P=0.047).  It was also noted that PrEP was more effective at reducing the occurrence of new HSV-2 infection in individuals who were with a less immune-compromised HIV-1 infected partner (CD4 count ≥0.350 x 109 cells/L).

More from this author: Rituximab not beneficial long-term in Sjorgen’s SyndromeHigh-energy shockwave therapy effective in treating shoulder calcific tendinitis 

RELATED REPORTS

The 2 Minute Medicine Podcast Episode 6

The Scan by 2 Minute Medicine®: The Genetics of Alzheimer’s Disease, the Silent Killer, a Holiday Blizzard and an HIV Vaccine on the Horizon

Risk scores perform moderately well in discriminating people living with HIV with higher vs lower cardiovascular disease risk

Image: PD 

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: AIDSherpesHIVTenofovir
Previous Post

Stem cell transplant may be effective in sickle cell disease

Next Post

Genetic and non-genetic risk factors associated with pediatric celiac disease [TEDDY study]

RelatedReports

2MM Podcast

The 2 Minute Medicine Podcast Episode 6

January 13, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Genetics of Alzheimer’s Disease, the Silent Killer, a Holiday Blizzard and an HIV Vaccine on the Horizon

January 11, 2023
Few high school students, young adults get HIV testing
Cardiology

Risk scores perform moderately well in discriminating people living with HIV with higher vs lower cardiovascular disease risk

January 3, 2023
Positive physician experience in the Pediatric AIDS Corps
Cardiology

Risk of cardiovascular pathology determined using advanced cardiovascular imaging limited by heterogeneity amongst patients with human immunodeficiency virus

September 17, 2022
Next Post
Celiac disease more prevalent in children with irritable bowel syndrome

Genetic and non-genetic risk factors associated with pediatric celiac disease [TEDDY study]

No benefit with glucocorticoid injection for spinal stenosis

No benefit with glucocorticoid injection for spinal stenosis

Preterm birth associated with elevated plasma insulin levels

Insulin pumps more effective than multiple daily injections in type II diabetics [OpT2mise trial]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options